News

2023-12-21 | Company

Sever Pharma Solutions Secures DEA License for Controlled Substances Handling in Putnam, CT

Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled release systems for highly potent drugs is pleased to announce the successful attainment of the Drug Enforcement Administration (DEA) license for its site in Putnam, CT.

Read more

2023-12-19 | Company

Company report 2022

During 2022, we initiated the expansion of the R&D capacity at our US site in Putnam and increased our capabilities with a new line for aseptic fill and finish. Read the full company report.

Read more

2023-10-18 | Company

Sever Pharma Solutions Expands Capabilities with Approval of New Aseptic Filling Line for High Potent Injectable Drugs in Malmo Site

We pleased to announce the approval by the Swedish Health authorities of its state-of-the-art aseptic filling line for syringes, specifically designed for high potent injectable drugs, at its Malmo site.

Read more

2023-10-11 | Company

New Director of Supply Chain Management

We are happy to announce that Kristian Ahlgren has been appointed as Director of Supply Chain Management.

Read more

2023-09-21 | Company

Sever Pharma Solutions breaks ground with new high potency drug manufacturing suites

[Putnam, CT, USA - Sever Pharma Solutions, a leading pharmaceutical contract development and manufacturing organization (CDMO), has announced the groundbreaking of its new high potency active pharmaceutical ingredients (HPAPI) manufacturing suites.

Read more

2023-09-13 | Company

Tony Listro interviewed in Drug Development & Delivery

Tony Listro, Vice President of Technology and Site Lead for SPS’s North American site in Putnam, CT, discusses the company’s recent focus areas and current expansion plans.

Read more

2023-07-07 | Company

Sustainability report 2022

Sustainability is front and center for a company of our kind. Subsequently, Sever Pharma Solutions is entirely focused on human health and well-being. Read the full sustainability report.

Read more

2022-10-13 | Company

Company report 2021

Our goal is to build a global CDMO with a niche strategy. There are few high-potency product manufacturers, and almost no one works with polymer implants. Read the full company report.

Read more